MedPath

Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal in ICU Setting

Not Applicable
Completed
Conditions
Penicillin Allergy
Interventions
Other: Penicillin Allergic Risk Stratification Best Practice Alert
Registration Number
NCT03702283
Lead Sponsor
Vanderbilt University Medical Center
Brief Summary

Currently it is estimated that at least 25 million people in the United States are labeled as penicillin allergic although less than 1.5 million of these are truly allergic. Although combined skin testing and oral challenge is an evidence-based de-labeling strategy the high burden of penicillin allergy labels means these services are available only through specialty allergy practices. There is therefore a need to provide evidence for alternative penicillin de-labeling strategies such as direct oral challenge. Previous studies have utilized quasi-experimental designs. Test dose challenges are currently recommended as a strategy for removal of low risk drug allergies, but the current experience is limited to single arm observational studies and evidence-based strategies for identifying low risk patients are lacking. The investigators objective is to demonstrate the benefit of providing risk stratification in removing penicillin allergy labels for low risk penicillin allergy patients in a single arm intervention pilot trial in the ICU setting, which will pave the way for a future stepped wedge randomized control trial (stepped wedge trial entered separately in clinical trials.gov as NCT03702270)

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
240
Inclusion Criteria
  • VUMC patients age 18 or older with a penicillin allergy reported in their chart and are medically stable, currently admitted to ICU.
Read More
Exclusion Criteria
  • Patients with a penicillin allergy reported in their chart under ICU care, but who are currently medically unstable.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Penicillin Allergic ICU PatientsPenicillin Allergic Risk Stratification Best Practice AlertThe intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
Primary Outcome Measures
NameTimeMethod
Penicillin Allergy Label RemovalHospital discharge at approximately 7 days after ICU transfer

The proportion of patients with low risk penicillin allergy whose labels are removed from the medical chart's allergy section.

Patients With Low Risk Penicillin Allergy Label Who Underwent Amoxicillin ChallengeHospital discharge at approximately 7 days after ICU transfer

The proportion of patients with low risk penicillin allergy who underwent amoxicillin challenge

Secondary Outcome Measures
NameTimeMethod
Communication About Penicillin Allergy in Discharge SummaryHospital discharge at approximately 7 days after ICU transfer

The proportion of penicillin allergic patients whose discharge summary contains information about penicillin allergy at discharge.

Adverse Events (in Particular, Reported Allergic Events)Hospital discharge at approximately 7 days after ICU transfer

The proportion of penicillin allergic patients challenged with amoxicillin who reported adverse events

Antibiotic Utilization by Patients2 years observation

The number of changes or new starts of penicillin treatments as a result of penicillin allergy label removal and the proportion of patients experiencing this event

Trial Locations

Locations (1)

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath